2 weeks Ago By ABMN Staff
Ascendis Pharma A/S ( NASDAQ:ASND – Get Free Report ) is set to issue its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($1.54) per share for the quarter.
Persons that wish to register for the company’s earnings conference call can do so using this link . Ascendis Pharma A/S ( NASDAQ:ASND – Get Free Report ) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.
05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51).
The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million.
On average, analysts expect Ascendis Pharma A/S to post $-7 EPS for the current fiscal year and $-4 EPS for the next fiscal year. Ascendis Pharma A/S Price Performance ASND stock opened at $127.67 on Wednesday.
Ascendis Pharma A/S has a 1-year low of $86.54 and a 1-year high of $161.00.
The business has a 50-day moving average price of $131.91 and a 200 day moving average price of $132.90.
The company has a market capitalization of $7.74 billion, a P/E ratio of -13.71 and a beta of 0.
66. Wall Street Analyst Weigh In Check Out Our Latest Stock Analysis on ASND Ascendis Pharma A/S Company Profile ( Get Free Report ) Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. See Also Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter .
.
